Shares of Guardian Pharmacy Services, Inc. (GRDN) are soaring 6.03% in pre-market trading on Thursday following the release of the company's strong fourth-quarter and full-year 2024 financial results, as well as positive guidance for 2025.
Guardian Pharmacy reported impressive Q4 2024 results, with revenue increasing 20% year-over-year to $339 million and adjusted EBITDA growing 30% to $26 million. The company's resident count grew 14% to approximately 186,000. For the full year 2024, Guardian generated revenue of $1.228 billion, up 17% from the previous year, and adjusted EBITDA of $91 million, representing a 19% increase.
Looking ahead, Guardian Pharmacy provided optimistic guidance for 2025, projecting revenue between $1.33 billion and $1.35 billion, and adjusted EBITDA ranging from $97 million to $101 million. The company's growth strategy, which includes organic expansion, greenfield startups, and strategic acquisitions, has contributed to its strong performance and positive outlook. Additionally, Truist Financial reiterated a Buy rating on GRDN stock, further boosting investor confidence. The company's success in streamlining its COVID and flu vaccination clinics, transforming them from a profitability headwind to a slight tailwind, has also impressed investors and analysts alike.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.